Cargando…

Bell's palsy during rechallenge of immune checkpoint inhibitor

INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemura, Kohji, Yamanaka, Taro, Hayashida, Michikata, Kizawa, Rika, Yamaguchi, Takeshi, Tanabe, Yuko, Sakaguchi, Kazushige, Suyama, Koichi, Urakami, Shinji, Miura, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978074/
https://www.ncbi.nlm.nih.gov/pubmed/36875003
http://dx.doi.org/10.1002/iju5.12572
_version_ 1784899433538781184
author Takemura, Kohji
Yamanaka, Taro
Hayashida, Michikata
Kizawa, Rika
Yamaguchi, Takeshi
Tanabe, Yuko
Sakaguchi, Kazushige
Suyama, Koichi
Urakami, Shinji
Miura, Yuji
author_facet Takemura, Kohji
Yamanaka, Taro
Hayashida, Michikata
Kizawa, Rika
Yamaguchi, Takeshi
Tanabe, Yuko
Sakaguchi, Kazushige
Suyama, Koichi
Urakami, Shinji
Miura, Yuji
author_sort Takemura, Kohji
collection PubMed
description INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune‐related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. CONCLUSION: Physicians should be aware that Bell's palsy can occur as an immune‐related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune‐related adverse events.
format Online
Article
Text
id pubmed-9978074
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99780742023-03-03 Bell's palsy during rechallenge of immune checkpoint inhibitor Takemura, Kohji Yamanaka, Taro Hayashida, Michikata Kizawa, Rika Yamaguchi, Takeshi Tanabe, Yuko Sakaguchi, Kazushige Suyama, Koichi Urakami, Shinji Miura, Yuji IJU Case Rep Case Reports INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune‐related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. CONCLUSION: Physicians should be aware that Bell's palsy can occur as an immune‐related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune‐related adverse events. John Wiley and Sons Inc. 2023-01-16 /pmc/articles/PMC9978074/ /pubmed/36875003 http://dx.doi.org/10.1002/iju5.12572 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Takemura, Kohji
Yamanaka, Taro
Hayashida, Michikata
Kizawa, Rika
Yamaguchi, Takeshi
Tanabe, Yuko
Sakaguchi, Kazushige
Suyama, Koichi
Urakami, Shinji
Miura, Yuji
Bell's palsy during rechallenge of immune checkpoint inhibitor
title Bell's palsy during rechallenge of immune checkpoint inhibitor
title_full Bell's palsy during rechallenge of immune checkpoint inhibitor
title_fullStr Bell's palsy during rechallenge of immune checkpoint inhibitor
title_full_unstemmed Bell's palsy during rechallenge of immune checkpoint inhibitor
title_short Bell's palsy during rechallenge of immune checkpoint inhibitor
title_sort bell's palsy during rechallenge of immune checkpoint inhibitor
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978074/
https://www.ncbi.nlm.nih.gov/pubmed/36875003
http://dx.doi.org/10.1002/iju5.12572
work_keys_str_mv AT takemurakohji bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT yamanakataro bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT hayashidamichikata bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT kizawarika bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT yamaguchitakeshi bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT tanabeyuko bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT sakaguchikazushige bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT suyamakoichi bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT urakamishinji bellspalsyduringrechallengeofimmunecheckpointinhibitor
AT miurayuji bellspalsyduringrechallengeofimmunecheckpointinhibitor